Skip to content
Surf Wiki
Save to docs
general/coagulopathies

From Surf Wiki (app.surf) — the open knowledge base

May–Hegglin anomaly


FieldValue
nameMay–Hegglin anomaly
synonymsDöhle leukocyte inclusions with giant platelets and Macrothrombocytopenia with leukocyte inclusions
imageMay-Hegglin smear 2009-11-13.JPG

May–Hegglin anomaly (MHA), is a rare genetic disorder of the blood platelets that causes them to be abnormally large.

Presentation

In the leukocytes, the presence of very small rods (around 3 micrometers), or Döhle-like bodies can be seen in the cytoplasm.

Pathogenesis

MHA is believed to be associated with the MYH9 gene. The pathogenesis of the disorder had been unknown until recently, when autosomal dominant mutations in the gene encoding non-muscle myosin heavy chain IIA (MYH9) were identified. Unique cytoplasmic inclusion bodies are aggregates of nonmuscle myosin heavy chain IIA, and are only present in granulocytes. These May-Hegglin inclusions are large, basophilic, cytoplasmic inclusions resembling Döhle bodies in the granulocytes. It is not yet known why inclusion bodies are not present in platelets, monocytes, and lymphocytes, or how giant platelets are formed. MYH9 is also found to be responsible for several related disorders with macrothrombocytopenia and leukocyte inclusions, including Sebastian, Fechtner, and Epstein syndromes, which feature deafness, nephritis, and/or cataract. MHA is also a feature of the Alport syndrome (hereditary nephritis with sensorineural hearing loss).Noris P et al. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998;104(4):355-60

Diagnosis

Treatment

May-Hegglin Anomaly can be treated by various methods:

  • Medication;Tranexamic Acid
  • Desmopressin Acetate
  • Platelet Transfusion will not work, because the affected platelets will overtake the new platelets.

History

MHA is named for German physician Richard May (January 7, 1863 – 1936) and Swiss physician Robert Hegglin. The disorder was first described by Richard May in 1909 and was subsequently described by Robert Hegglin in 1945.

References

References

  1. {{OMIM. 155100
  2. (Apr 2008). "Historical hematology: May-Hegglin anomaly". American Journal of Hematology.
  3. Gülen H, Erbay A, Kazancı E, Vergin C. (2006). "A rare familial thrombocytopenia: May-Hegglin anomaly report of two cases and review of the literature.". Turk J Haematol.
  4. {{WhoNamedIt. synd. 113
  5. R. May. Leukocyteneinschlüsse. Kasuistische Mitteilung. Deutsches Archiv für klinische Medizin, Leipzig, 1909, 96: 1-6.
  6. R. Hegglin. Über eine neue Form einer konstitutionellen Leukozytenanomalie, kombiniert mit Throbopathie. Schweizerische medizinische Wochenschrift, Basel, 1945, 75: 91-92.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about May–Hegglin anomaly — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report